塞德斯医疗(CLDX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CLDX 塞德斯医疗

休市中 02-27 16:00:00 EST

30.09

-0.55

-1.80%

盘后28.67

-1.42-4.71%

18:34 EST

最高30.46	最低29.43	成交量137.90万
今开30.15	昨收30.64	日振幅3.36%
总市值19.99亿	流通市值16.01亿	总股本6,645万
成交额4,131万	换手率2.59%	流通股本5,321万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CLDX","market":"US","secType":"STK","nameCN":"塞德斯医疗","latestPrice":30.09,"timestamp":1772226000000,"preClose":30.64,"halted":0,"volume":1378953,"hourTrading":{"tag":"盘后","latestPrice":28.6725,"preClose":30.09,"latestTime":"18:34 EST","volume":271799,"amount":8177373.6183,"timestamp":1772235290542,"change":-1.4175,"changeRate":-0.047109,"amplitude":0.047109},"delay":0,"changeRate":-0.01795039164490864,"floatShares":53206696,"shares":66449471,"eps":-3.9,"marketStatus":"休市中","change":-0.55,"latestTime":"02-27 16:00:00 EST","open":30.15,"high":30.455,"low":29.425,"amount":41309670.096216,"amplitude":0.033616,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.9,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":515304000000,"exchange":"NASDAQ","adjPreClose":30.64,"preHourTrading":{"tag":"盘前","latestPrice":30.64,"preClose":30.64,"latestTime":"09:24 EST","volume":146,"amount":4424.649574,"timestamp":1772202295424,"change":0,"changeRate":0,"amplitude":0.038554},"postHourTrading":{"tag":"盘后","latestPrice":28.6725,"preClose":30.09,"latestTime":"18:34 EST","volume":271799,"amount":8177373.6183,"timestamp":1772235290542,"change":-1.4175,"changeRate":-0.047109,"amplitude":0.047109},"volumeRatio":0.8798341560793376,"impliedVol":0.8766,"impliedVolPercentile":0.9203},"requestUrl":"/m/hq/s/CLDX","defaultTab":"news","newsList":[{"id":"1128016919","title":"塞德斯医疗完成Barzolvolimab治疗慢性自发性荨麻疹全球III期研究（Embarq-Csu1与Embarq-Csu2）患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1128016919","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128016919?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:11","pubTimestamp":1772021493,"startTime":"0","endTime":"0","summary":"塞德斯医疗（Celldex Therapeutics）已顺利完成其创新药物Barzolvolimab针对慢性自发性荨麻疹的两项全球III期临床研究——Embarq-Csu1与Embarq-Csu2的患者招募工作。这一重要进展标志着该疗法在验证其疗效与安全性的关键阶段迈出了坚实一步，为后续数据分析和监管申报奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2607580860","title":"塞德斯医疗盘中异动 大幅下挫5.03%报24.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607580860","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607580860?lang=zh_cn&edition=full","pubTime":"2026-01-29 03:30","pubTimestamp":1769628629,"startTime":"0","endTime":"0","summary":"北京时间2026年01月29日03时30分，塞德斯医疗股票出现波动，股价大幅跳水5.03%。截至发稿，该股报24.91美元/股，成交量17.5489万股，换手率0.26%，振幅4.82%。机构评级方面，在所有15家参与评级的机构中，80%的券商给予买入建议，13%的券商给予持有建议，7%的券商给予卖出建议。塞德斯医疗股票所在的生物技术行业中，整体跌幅为0.75%。塞德斯医疗公司简介：Celldex Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012903302997a3d561&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012903302997a3d561&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"1111014089","title":"拜耳与Souffle Therapeutics达成战略合作 共同推进细胞特异性心脏靶向siRNA疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1111014089","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111014089?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:46","pubTimestamp":1767858391,"startTime":"0","endTime":"0","summary":"1月8日，拜耳公司与Souffle Therapeutics宣布达成战略合作，双方将共同推进细胞特异性心脏靶向siRNA疗法的研发。此次合作重点聚焦于开发针对特定类型扩张型心肌病的潜在最佳siRNA疗法，旨在打造同类最优治疗方案。\n目前，双方尚未披露此次合作的具体财务细节。该合作将结合拜耳在心血管领域的专业优势与Souffle Therapeutics在siRNA技术平台的创新实力，共同探索心脏靶向治疗的新突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"1175573108","title":"塞德斯医疗启动巴佐洛单抗在冷荨麻疹和症状性皮肤划痕症中的全球注册三期研究计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1175573108","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175573108?lang=zh_cn&edition=full","pubTime":"2025-12-09 21:05","pubTimestamp":1765285504,"startTime":"0","endTime":"0","summary":"塞德斯医疗启动巴佐洛单抗在冷荨麻疹和症状性皮肤划痕症中的全球注册三期研究计划","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"1162895924","title":"塞德斯医疗：在第二阶段研究中，所有主要和次要终点在12周时均达到高度统计学显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1162895924","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162895924?lang=zh_cn&edition=full","pubTime":"2025-11-06 21:06","pubTimestamp":1762434375,"startTime":"0","endTime":"0","summary":"塞德斯医疗：在第二阶段研究中，所有主要和次要终点在12周时均达到高度统计学显著性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"1110473082","title":"塞德斯医疗公布Barzolvolimab在寒冷荨麻疹和症状性皮肤反应中的二期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1110473082","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110473082?lang=zh_cn&edition=full","pubTime":"2025-11-06 21:05","pubTimestamp":1762434317,"startTime":"0","endTime":"0","summary":"塞德斯医疗公布Barzolvolimab在寒冷荨麻疹（Coldu）和症状性皮肤反应（Sd）中的二期研究结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"1186475880","title":"塞德斯医疗公布Cdx-622一期临床试验初步积极结果，显示良好的安全性和药代动力学特征以及持续的肥大细胞抑制作用","url":"https://stock-news.laohu8.com/highlight/detail?id=1186475880","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186475880?lang=zh_cn&edition=full","pubTime":"2025-10-31 04:02","pubTimestamp":1761854542,"startTime":"0","endTime":"0","summary":"塞德斯医疗公布Cdx-622一期临床试验的初步积极结果，显示该药物具有良好的安全性和药代动力学特征，并且能够有效持续抑制肥大细胞。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"1168418426","title":"Pluri子公司Coffeesai与恰帕斯咖啡研究所合作推进墨西哥细胞基咖啡制造","url":"https://stock-news.laohu8.com/highlight/detail?id=1168418426","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168418426?lang=zh_cn&edition=full","pubTime":"2025-10-08 21:29","pubTimestamp":1759930174,"startTime":"0","endTime":"0","summary":"Pluri Inc.子公司Coffeesai与恰帕斯咖啡研究所宣布建立战略合作关系，共同推进墨西哥的细胞基咖啡制造技术。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLUR","CLDX","BK4139"],"gpt_icon":0},{"id":"2518204665","title":"塞德斯医疗盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518204665","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518204665?lang=zh_cn&edition=full","pubTime":"2025-03-11 03:08","pubTimestamp":1741633698,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日03时08分，塞德斯医疗股票出现波动，股价快速跳水5.06%。截至发稿，该股报19.63美元/股，成交量35.8184万股，换手率0.54%，振幅6.56%。机构评级方面，在所有13家参与评级的机构中，85%的券商给予买入建议，15%的券商给予持有建议，无券商给予卖出建议。塞德斯医疗股票所在的生物技术行业中，整体涨幅为0.16%。塞德斯医疗公司简介：Celldex Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311030818abf377b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311030818abf377b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2517430909","title":"塞德斯医疗2024财年实现净利润-1.58亿美元，同比减少12.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517430909","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517430909?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363252,"startTime":"0","endTime":"0","summary":"3月8日，塞德斯医疗公布财报，公告显示公司2024财年净利润为-1.58亿美元，同比减少12.06%；其中营业收入为7.02百万美元，同比增加2.03%，每股基本收益为-2.45美元。从资产负债表来看，塞德斯医疗总负债45.34百万美元，其中短期债务1.45百万美元，资产负债比为0.18，流动比率为0.19。机构评级：截至2025年3月8日，当前有11家机构对塞德斯医疗目标价做出预测，其中目标均价为63.55美元，其中最低目标价为36.00美元，最高目标价为90.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000224a2647f73&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000224a2647f73&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLDX"],"gpt_icon":0},{"id":"2517922121","title":"塞德斯医疗盘中异动 大幅拉升5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517922121","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517922121?lang=zh_cn&edition=full","pubTime":"2025-03-07 03:49","pubTimestamp":1741290556,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日03时49分，塞德斯医疗股票出现波动，股价快速上涨5.12%。截至发稿，该股报22.18美元/股，成交量34.6693万股，换手率0.52%，振幅6.40%。机构评级方面，在所有13家参与评级的机构中，85%的券商给予买入建议，15%的券商给予持有建议，无券商给予卖出建议。塞德斯医疗股票所在的生物技术行业中，整体跌幅为0.45%。塞德斯医疗公司简介：Celldex Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307034917a262db95&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307034917a262db95&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"1119355239","title":"异动解读 | 生物技术公司塞德斯医疗(CLDX)盘中大涨5% 有望受益营收净利改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1119355239","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119355239?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:30","pubTimestamp":1741199422,"startTime":"0","endTime":"0","summary":"生物技术公司塞德斯医疗(CLDX)今日盘中股价出现大涨行情,最高涨幅达5%。此次股价上扬或与公司基本面改善预期有关。\n\n根据最新财报显示,塞德斯医疗当季营业收入达到702万美元,同比有所改善。尽管仍处于亏损状态,但净亏损额较上一季度有所收窄。公司治疗管线产品也取得一定进展,预计未来将带动营收增长。\n\n与此同时,投行机构普遍对该股持乐观态度,多数机构给予\"买入\"评级,反映出市场对公司长期前景的看好。该股所属生物技术行业整体也呈现上涨态势,有望为塞德斯医疗股价提供支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 生物技术公司塞德斯医疗(CLDX)盘中大涨5% 有望受益营收净利改善","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CLDX"],"gpt_icon":0},{"id":"2517288979","title":"塞德斯医疗盘中异动 下午盘快速上涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517288979","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517288979?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:25","pubTimestamp":1741199120,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日02时25分，塞德斯医疗股票出现异动，股价快速上涨5.00%。截至发稿，该股报21.00美元/股，成交量27.6287万股，换手率0.42%，振幅4.75%。机构评级方面，在所有13家参与评级的机构中，85%的券商给予买入建议，15%的券商给予持有建议，无券商给予卖出建议。塞德斯医疗股票所在的生物技术行业中，整体涨幅为1.34%。塞德斯医疗公司简介：Celldex Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306022520abe9f365&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306022520abe9f365&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"1126254127","title":"异动解读 | 塞德斯医疗盘中大跌5.93% 业绩疲软或是主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1126254127","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126254127?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:46","pubTimestamp":1741034819,"startTime":"0","endTime":"0","summary":"塞德斯医疗(CLDX)公司股价周一盘中出现大跌,跌幅高达5.93%,引发了市场的广泛关注。\n\n作为一家专注于癌症免疫治疗的生物制药公司,塞德斯医疗近期公布的财报数据表现并不理想。公司2024年全年营业收入仅为702万美元,净利润则高达亏损1.58亿美元,每股收益为负2.45美元。业绩疲软或许是导致公司股价大跌的主要原因。\n\n不过,值得关注的是,大部分机构分析师仍看好塞德斯医疗的长期发展前景。在参与评级的13家机构中,高达85%的券商给予该股买入评级,仅有15%的券商持有观望态度。分析人士认为,公司在肿瘤免疫治疗领域拥有一定的技术储备,如果能在产品上取得突破,股价未来仍有较大的上涨空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 塞德斯医疗盘中大跌5.93% 业绩疲软或是主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CLDX"],"gpt_icon":0},{"id":"2516639316","title":"塞德斯医疗盘中异动 下午盘股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516639316","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516639316?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:25","pubTimestamp":1741033535,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时25分，塞德斯医疗股票出现波动，股价快速下挫5.01%。截至发稿，该股报19.54美元/股，成交量48.7449万股，换手率0.73%，振幅8.14%。机构评级方面，在所有13家参与评级的机构中，85%的券商给予买入建议，15%的券商给予持有建议，无券商给予卖出建议。塞德斯医疗股票所在的生物技术行业中，整体涨幅为0.08%。塞德斯医疗公司简介：Celldex Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040425359637fb44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040425359637fb44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2514354366","title":"Celldex Therapeutics(CLDX.US)：2024年Q4财报实现营收117.5万美元，前值为413.2万美元，预期值为131万美元；每股收益为-0.71美元，前值为-0.83美元，预期值为-0.73美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514354366","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514354366?lang=zh_cn&edition=full","pubTime":"2025-02-28 07:08","pubTimestamp":1740697722,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics(CLDX.US)：2024年Q4财报实现营收117.5万美元，前值为413.2万美元，预期值为131万美元；每股收益为-0.71美元，前值为-0.83美元，预期值为-0.73美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28070848442548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CLDX","LENZ"],"gpt_icon":0},{"id":"2514705210","title":"塞德斯医疗盘中异动 股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514705210","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514705210?lang=zh_cn&edition=full","pubTime":"2025-02-25 04:54","pubTimestamp":1740430489,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时54分，塞德斯医疗股票出现异动，股价急速跳水5.03%。截至发稿，该股报21.33美元/股，成交量38.589万股，换手率0.58%，振幅5.39%。机构评级方面，在所有13家参与评级的机构中，85%的券商给予买入建议，15%的券商给予持有建议，无券商给予卖出建议。塞德斯医疗股票所在的生物技术行业中，整体跌幅为0.40%。塞德斯医疗公司简介：Celldex Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225045449a252640f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225045449a252640f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2511341529","title":"塞德斯医疗盘中异动 大幅上涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511341529","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511341529?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:56","pubTimestamp":1739458573,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时56分，塞德斯医疗股票出现波动，股价大幅上涨5.12%。截至发稿，该股报23.40美元/股，成交量8.5876万股，换手率0.13%，振幅4.18%。机构评级方面，在所有12家参与评级的机构中，83%的券商给予买入建议，17%的券商给予持有建议，无券商给予卖出建议。塞德斯医疗股票所在的生物技术行业中，整体涨幅为0.21%。塞德斯医疗公司简介：Celldex Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213225613a244b176&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213225613a244b176&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2511523016","title":"Celldex Therapeutics(CLDX.US)获瑞银首次覆盖，给予买入评级, 目标价44.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511523016","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511523016?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:23","pubTimestamp":1739456591,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics(CLDX.US)获瑞银首次覆盖，给予买入评级, 目标价44.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/13222348149089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CLDX","LENZ"],"gpt_icon":0},{"id":"2510865085","title":"塞德斯医疗盘中异动 股价大跌5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510865085","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510865085?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:41","pubTimestamp":1739198502,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时41分，塞德斯医疗股票出现波动，股价急速下跌5.47%。截至发稿，该股报21.24美元/股，成交量6.0842万股，换手率0.09%，振幅7.92%。机构评级方面，在所有12家参与评级的机构中，83%的券商给予买入建议，17%的券商给予持有建议，无券商给予卖出建议。塞德斯医疗股票所在的生物技术行业中，整体涨幅为0.00%。塞德斯医疗公司简介：Celldex Therapeutics Inc是一家生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210224142a240a49c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210224142a240a49c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CLDX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.celldex.com","stockEarnings":[{"period":"1week","weight":0.3071},{"period":"1month","weight":0.2148},{"period":"3month","weight":0.1136},{"period":"6month","weight":0.3628},{"period":"1year","weight":0.4815},{"period":"ytd","weight":0.1079}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Celldex Therapeutics, Inc.在特拉华州注册成立。该公司是一家生物制药公司，致力于探索肥大细胞生物学的科学并开发治疗性抗体，这些抗体具有参与人体免疫系统并直接影响关键途径的能力，以改善患有严重炎症、过敏、自身免疫和其他破坏性疾病的患者的生活。该公司的候选药物包括单克隆和双特异性抗体，旨在解决现有治疗方法不足的肥大细胞介导疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.55,"avgChangeRate":0.123409},{"month":2,"riseRate":0.425,"avgChangeRate":-0.00139},{"month":3,"riseRate":0.461538,"avgChangeRate":0.003323},{"month":4,"riseRate":0.487179,"avgChangeRate":0.002303},{"month":5,"riseRate":0.282051,"avgChangeRate":-0.021096},{"month":6,"riseRate":0.5,"avgChangeRate":0.145989},{"month":7,"riseRate":0.425,"avgChangeRate":-0.012999},{"month":8,"riseRate":0.375,"avgChangeRate":-0.027935},{"month":9,"riseRate":0.325,"avgChangeRate":-0.018185},{"month":10,"riseRate":0.5,"avgChangeRate":0.004664},{"month":11,"riseRate":0.575,"avgChangeRate":0.057317},{"month":12,"riseRate":0.45,"avgChangeRate":-0.008619}],"exchange":"NASDAQ","name":"塞德斯医疗","nameEN":"Celldex Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"塞德斯医疗(CLDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供塞德斯医疗(CLDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"塞德斯医疗,CLDX,塞德斯医疗股票,塞德斯医疗股票老虎,塞德斯医疗股票老虎国际,塞德斯医疗行情,塞德斯医疗股票行情,塞德斯医疗股价,塞德斯医疗股市,塞德斯医疗股票价格,塞德斯医疗股票交易,塞德斯医疗股票购买,塞德斯医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"塞德斯医疗(CLDX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供塞德斯医疗(CLDX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}